Amylyx Pharmaceuticals, INC Form 4 insider transactions

Amylyx Pharmaceuticals, Inc. Director Daphne Quimi was granted 25,000 stock options with an exercise price of $5.05, vesting by June 2026 or the next annual meeting.

Amylyx Pharmaceuticals, Inc. Director George M. Milne Jr. was granted 25,000 stock options with an exercise price of $5.05, vesting by June 2026.

Amylyx Pharmaceuticals' Chief Legal Officer, Gina Mazzariello, reported gifting 1,000 shares of common stock on May 22, 2025, for no consideration.

James M. Frates, CFO of Amylyx Pharmaceuticals, sold 10,896 shares of common stock on March 31, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Camille L. Bedrosian, Chief Medical Officer of Amylyx Pharmaceuticals, sold shares to cover tax withholding obligations related to vesting restricted stock units.

Gina Mazzariello, Chief Legal Officer of Amylyx Pharmaceuticals, sold 9,192 shares of common stock on March 31, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Joshua B. Cohen, Co-CEO of Amylyx Pharmaceuticals, sold shares to cover tax withholding obligations related to the vesting of restricted stock units.

Amylyx Pharmaceuticals' Co-CEO, Justin B. Klee, sold shares of common stock on March 31, 2025, to cover tax withholding obligations related to the vesting of restricted stock units.

Director Bernhardt G. Zeiher of Amylyx Pharmaceuticals, Inc. purchased 10,000 shares of common stock at a weighted average price of $3.7005 on March 20, 2025.

Gina Mazzariello, Chief Legal Officer of Amylyx Pharmaceuticals, reports the acquisition of stock options and restricted stock units.

Chief Medical Officer of Amylyx Pharmaceuticals, Camille L Bedrosian, reports acquisition of restricted stock units and stock options, along with disposal of common stock.

Co-CEO of Amylyx Pharmaceuticals, Justin B. Klee, reports acquiring shares and stock options in the company.

Joshua Cohen, Co-CEO of Amylyx Pharmaceuticals, reports acquiring shares and stock options in the company.

Chief Financial Officer of Amylyx Pharmaceuticals, James M. Frates, reports acquisition of restricted stock units and stock options, along with adjustments to beneficial ownership.

Co-CEO of Amylyx Pharmaceuticals, Justin B. Klee, reports the sale of shares to cover tax withholding obligations related to vesting restricted stock units.

Joshua B. Cohen, Co-CEO of Amylyx Pharmaceuticals, sold shares to cover tax withholding obligations related to the vesting of restricted stock units.

Gina Mazzariello, Chief Legal Officer of Amylyx Pharmaceuticals, sold 1,611 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Gina Mazzariello, Chief Legal Officer of Amylyx Pharmaceuticals, sold 4,169 shares of common stock on February 24, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Justin B. Klee, Co-CEO of Amylyx Pharmaceuticals, exercised stock options on February 5, 2025, acquiring 36,310 shares of common stock.

Gina Mazzariello, Chief Legal Officer of Amylyx Pharmaceuticals, sold 3,678 shares of common stock on February 3, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Joshua Cohen, Co-CEO of Amylyx Pharmaceuticals, sold shares to cover tax withholding obligations related to the vesting of restricted stock units.

Co-CEO of Amylyx Pharmaceuticals, Justin B. Klee, sold shares to cover tax withholding obligations related to the vesting of restricted stock units.

Director George M. Milne Jr. reports a gift of Amylyx Pharmaceuticals common stock, while holding a significant number of shares subject to a lock-up agreement.

Amylyx Pharmaceuticals Co-Chief Executive Officer, Justin B. Klee, sold 7,471 shares of common stock to cover tax obligations related to vesting restricted stock units.

Amylyx Pharmaceuticals Co-Chief Executive Officer, Joshua B. Cohen, sold 7,471 shares to cover tax obligations related to vesting restricted stock units.

Amylyx Pharmaceuticals' Chief Medical Officer, Camille L. Bedrosian, sold 5,421 shares of common stock to cover tax obligations related to vesting restricted stock units.

Justin B. Klee, Co-CEO of Amylyx Pharmaceuticals, exercised stock options on November 4, 2024, acquiring 63,690 shares of common stock.

Justin B. Klee, Co-CEO of Amylyx Pharmaceuticals, sold shares to cover tax withholding obligations related to the vesting of restricted stock units.

Joshua Cohen, Co-CEO of Amylyx Pharmaceuticals, sold shares of common stock on September 30, 2024, to cover tax withholding obligations related to the vesting of restricted stock units.

Chief Medical Officer of Amylyx Pharmaceuticals, Camille L Bedrosian, sold shares to cover tax withholding obligations related to vesting restricted stock units.